Dr. Agarwal's Health Care has completed the formal regulatory disclosure process for the inter-se transfer of shares between promoter group members. Dr. Anosh Agarwal filed the mandatory disclosure under Regulation 29(2) of SEBI (SAST) Regulations, 2011 on March 6, 2026, following the transfer of 21,15,180 shares to Dr. Athiya Agarwal.

Transaction Overview

The share transfer was executed on March 4, 2026, as a gift transaction between immediate relatives within the promoter group. The acquisition represents 0.67% of the company's total share capital and was completed under SEBI's exemption provisions for inter-se transfers among promoters.

Shareholding Changes

The formal disclosure reveals the complete shareholding pattern changes resulting from the transaction. Dr. Anosh Agarwal's stake decreased from 5.36% to 4.69% of the total share capital following the transfer.

Regulatory Compliance

The company has fulfilled all mandatory disclosure requirements under SEBI regulations. The formal disclosure under Regulation 29(2) was submitted to BSE Limited and National Stock Exchange of India Limited on March 6, 2026. The transaction maintains compliance as it involves immediate relatives within the promoter group, ensuring no change in the overall promoter group shareholding.

The company's equity share capital remains unchanged at 31,68,07,506 equity shares of Re. 1/- each, aggregating to Rs. 31,68,07,506. The shares continue to be listed on both BSE Limited and National Stock Exchange of India Limited.

Dr. Agarwal's Health Care Limited has received a regulatory report from Dr. Athiya Agarwal under SEBI SAST Regulation 10(6) confirming the completion of an inter-se share transfer. The transaction, completed on February 24, 2026, involved the acquisition of 14,85,822 shares representing 0.47% of the company's share capital through a gift transfer from Dr. Anosh Agarwal.

Transaction Completion Details

The completed share transfer represents an inter-se transfer between promoter group members who are immediate relatives. Dr. Athiya Agarwal filed the regulatory report on February 26, 2026, with both BSE Limited and National Stock Exchange of India Limited, confirming the completion of the previously disclosed transaction.

Regulatory Compliance Framework

The transaction was executed under the exemption provided in Regulation 10(1)(a)(i) of SEBI SAST Regulations, 2011, which covers inter-se transfers of shares amongst immediate relatives. Dr. Athiya Agarwal had previously filed the required prior intimation under Regulation 10(5) on February 6, 2026, within the specified timeline.

Updated Shareholding Pattern

The inter-se transfer has resulted in changes to individual shareholdings within the promoter group while maintaining the overall promoter group shareholding percentage. The regulatory filing confirms that there has been no change in the total shareholding of the promoter and promoter group after the inter-se transfer.

Stock Exchange Notification

The regulatory report was filed with both BSE Limited (Company Code: 544350) and National Stock Exchange of India Limited (Company Symbol: AGARWALEYE). The filing confirms that all disclosure requirements under SEBI SAST Regulations have been fulfilled, including the prior intimation and post-transaction reporting obligations.

The completed transaction represents a straightforward reorganization of shareholding within the promoter group, with no impact on the company's operational structure or public shareholding pattern. The gift transfer eliminates the requirement for making an open offer to public shareholders under the immediate relatives exemption provision.